SEC Comment Letter 0000000000-23-005266 to Astria Therapeutics, Inc. (ATXS) (CIK 0001454789)
Astria Therapeutics, Inc. (ATXS) (CIK 0001454789)
Date: May 17, 2023 · CIK: 0001454789 · Accession: 0000000000-23-005266
AI Filing Summary & Sentiment
File numbers found in text: 333-267546
Letter
United States securities and exchange commission logo May 17, 2023 Jill Milne President and Chief Executive Officer Astria Therapeutics, Inc. 75 State Street, Suite 1400 Boston, Massachusetts 02109 Re:Astria Therapeutics, Inc. Registration Statement on Form S-3 Filed May 11, 2023 File No. 333-267546 Dear Jill Milne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Cindy Polynice at 202-551-8707 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary G. Reilly, Esq.
Show Raw Text
United States securities and exchange commission logo
May 17, 2023
Jill Milne
President and Chief Executive Officer
Astria Therapeutics, Inc.
75 State Street, Suite 1400
Boston, Massachusetts 02109
Re:Astria Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 11, 2023
File No. 333-267546
Dear Jill Milne:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Cindy Polynice at 202-551-8707 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rosemary G. Reilly, Esq.